Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
RATIONALE: Cancers of the oral cavity represent 30% of head and neck carcinomas in the western world. The oropharynx is the posterior continuation of the oral cavity and connects with the nasopharynx (above) and laryngopharynx (below). It is also a frequent site of primary head and neck cancers. These structures play a crucial role in swallowing, breath and speech. Locally advanced oropharyngeal cancers can obstruct the air flow or infiltrate muscles or nerves, which significantly disturb local functions. The incidence of Head and Neck Squamous Cell Cancer in patients older 65 years is high, 47% occurred in this population as recorded by the Surveillance, Epidemiology, and End Results registries in the United States. Regarding the therapeutic strategies, the association of radiotherapy with chemotherapy or biologics has demonstrated significant improvement of outcomes with the drawback of higher toxicity, or as demonstrated by 2 meta-analyses, without survival improvement in older patients. NBTXR3 and radiation therapy may increase the cancer cell killing and complete tumor shrinkage allowing a definitive treatment and preservation of local structures and functions in patients older 65 years, who cannot receive cisplatin.
Full description
Patients will receive a single administration of NBTXR3 on day 1,as an intratumor injection, followed by Intensity Modulated Radiation Therapy starting 24 hours later (Day 2), and up to completion of 7 weeks, i.e. 70 Grays, 2Grays/fraction. Patients whose tumor has completely shrunk will be followed for the post-radiotherapy evaluation up to the End of Treatment visit. Those patients whose tumor has not shrunk more than 50% of the baseline size, will stop the radiotherapy and may have a salvage tumor surgery. Then, all patients will be followed every 8 weeks, for the safety evaluation and cancer disease status until the end of the study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients aged ≥ 70 years old, or
Patients aged ≥ 65 years old and < 70 years old who are unable to receive cisplatin, or
Patients who have contraindication to cisplatin or that are intolerant to cisplatin or cetuximab or that cannot receive the combination of chemoradiation, regardless the age
Histologically or cytologically confirmed squamous cell carcinoma (SCC) of the oral cavity or oropharynx
T3 or T4 primary tumor or Stage III or IVA according to AJCC guidelines (8th Edition, 2018)
No evidence of distant metastatic disease, as determined by a negative PET scan or CT scan
Clinically eligible for intratumor implantation by injection
Karnofsky Performance Status ≥ 70
Adequate function of Bone marrow:
Adequate function of Kidney:
o Creatinine < or = 3.0 x ULN or creatinine clearance > or = 30 mL/min/1.73m²
Adequate function of the liver:
Negative pregnancy test ≤ 7 days of NBTXR3 injection in all females of child-bearing potential
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
75 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal